U.S. Markets open in 8 hrs 11 mins

Pernix Therapeutics downgraded to Hold from Buy at Cantor

Cantor downgraded Pernix Therapeutics following the company's weaker than expected Q4 results and 2013 outlook. The firm lowered its price target for shares to $7 from $15.